Novartis Acquires Excellergy for $2 Billion in Latest Biotech M&A Push

Mar 27, 2026 11:43 UTC

XLV, BMY, JNJ, AMGN

Short term

Novartis has agreed to acquire immunology-focused biotech Excellergy for $2 billion, marking its second major acquisition in as many days. The deal underscores growing confidence in next-generation immunology therapies across the pharmaceutical sector.

Novartis acquired Excellergy for $2 billion
The deal focuses on immunology and next-generation allergy treatments
This marks Novartis’s second multi-billion dollar acquisition in one week
The transaction is part of a broader trend of large-scale M&A in healthcare
The deal may impact biotech and pharma equities, including XLV, BMY, JNJ, AMGN
No specific therapy details were disclosed in the announcement

Novartis has entered into a definitive agreement to acquire Excellergy, a biotechnology company specializing in immunology, for $2 billion in cash. The acquisition represents a significant strategic move by the Swiss pharmaceutical giant to strengthen its pipeline in allergy and immune-related treatments. While details on the specific therapy remain undisclosed, the deal reflects Novartis’s bet on innovative, potentially faster-acting solutions in the immunology space. This transaction follows another major biotech acquisition announced earlier in the week, highlighting a surge in large-scale mergers and acquisitions within the healthcare sector. The move is expected to influence investor sentiment across the biotech and pharmaceutical landscape, particularly for companies with advanced immunology platforms. The acquisition could reshape competitive dynamics, driving sector-wide momentum and valuation adjustments for similar firms.